Hexarelin · Research brief

Hexarelin Before and After: What the Research Shows

Real Peptides Research TeamEditorial

Updated September 22, 20269 min read

50 WORDS

Short answer

Search hexarelin before and after and you'll mostly land on forum photo grids. The published record on this hexapeptide contains something far less glamorous and considerably more useful: serum growth hormone curves, receptor binding assays, and cardiac measurements in animal models, recorded before and after administration under controlled laboratory conditions.

Key takeaways

Hexarelin is a synthetic hexapeptide (CAS 140703-51-1, approximately 887 g/mol) that acts as a GHS-R1a agonist, the same receptor ghrelin binds.
A hexarelin before and after in the published literature means paired biochemical measurements such as serum GH and IGF-1, not photographic comparison.
Research published in Circulation Research identified CD36, a cardiac scavenger receptor, as the mediator of hexarelin's cardiovascular actions, which appear independent of the GH axis.
The GH response to hexarelin is reported to attenuate with repeated administration, with partial recovery after a washout period, which limits how far acute data extrapolates.
Hexarelin vs tesamorelin is a receptor comparison, not a potency contest: hexarelin acts at GHS-R1a while tesamorelin, a 44-amino-acid GHRH analogue, acts at the GHRH receptor.
Real Peptides does not publish hexarelin dosage guidance because these are research-use-only compounds; certificate of analysis data, CAS verification, and mg-per-mL concentration are the appropriate reference points.

Our team supplies hexarelin to research laboratories, and this is the single question we field most often about the compound. The distance between what the search phrase implies and what the literature documents is where nearly all of the confusion sits.

What does 'hexarelin before and after' mean in a research context?

Hexarelin before and after describes paired measurements, usually serum growth hormone and IGF-1, taken from the same subject prior to and following administration in a controlled study. Hexarelin is a growth hormone secretagogue receptor (GHS-R1a) agonist, so the primary recorded change is an acute pulse of pituitary GH release.

The common oversimplification is treating this as a body-composition question. Published hexarelin work rarely measures body composition at all. It measures endocrine response, and separately, cardiac tissue effects that appear to travel through an entirely different receptor. What follows covers the GHS-R1a and CD36 mechanisms, what studies of the original hexarelin reported, how hexarelin vs tesamorelin compare structurally and functionally, and why the hexarelin dosage question has no answer we are able to give.

Where the original hexarelin came from, and how it acts on the pituitary

Hexarelin (also called examorelin, CAS 140703-51-1) is a synthetic hexapeptide developed in the early 1990s within the growth hormone releasing peptide (GHRP) line that began with GHRP-6. Its sequence is His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2: six amino acids, molecular weight around 887 g/mol. The D-amino acid substitutions and the C-terminal amidation aren't decorative. They slow the enzymatic degradation that would otherwise clear a short native peptide almost immediately.

The receptor came after the peptide. GHS-R1a, the growth hormone secretagogue receptor, was characterized as the binding site for this peptide class before ghrelin, its endogenous ligand, was identified in 1999. That sequence of discovery matters when reading older work on the original hexarelin: those papers describe a receptor that had no known natural hormone yet.

The mechanism itself is specific. GHS-R1a is a Gq-coupled receptor expressed on pituitary somatotrophs and in the hypothalamic arcuate nucleus. Activation drives phospholipase C, then IP3, then a rise in intracellular calcium, which triggers GH release, while also reducing somatostatin tone. That is a separate pathway from the GHRH receptor, which is Gs-coupled and signals through cAMP. Two different doors into the same room.

There's a second binding site that most summaries skip. Research published in Circulation Research identified CD36, a scavenger receptor expressed in cardiac tissue and macrophages, as the receptor mediating hexarelin's cardiovascular actions. Our team has worked with researchers who procure hexarelin specifically for CD36 receptor biology, with no interest in the GH axis whatsoever.

What a hexarelin before and after actually measures in the literature

The endpoints are biochemical, not visual. Published hexarelin work records serum GH concentration at timed intervals following administration, IGF-1 as a downstream marker, and in the cardiac literature, measures such as left ventricular function in rodent models. A hexarelin before and after in this sense is a curve on a chart.

One finding changes how those curves should be read. Studies report that the GH response to hexarelin attenuates with repeated administration, with partial recovery after a washout interval, and receptor-level desensitization is the most commonly cited explanation. The design consequence is blunt: an acute single-administration comparison tells you very little about what the same measurement looks like in week three.

The mistake we see most often in this space isn't a handling error or a purity issue. It's investigators comparing acute-response data against a chronic-exposure endpoint, then reading the mismatch as a compound or supplier problem when it's a pharmacology problem that the literature already predicted.

There's a second confound worth naming. The GHRP class is reported to elevate cortisol and prolactin alongside GH, and hexarelin is described in the literature as less selective in this respect than Ipamorelin. An endocrine panel measuring GH alone misses that completely.

And some of the most interesting hexarelin before and after data comes from models with no functioning GH axis at all. Cardiac effects reported in hypophysectomized and GH-deficient rat models point to activity that doesn't require growth hormone to occur, which remains the strongest argument that hexarelin is not simply a GH-release tool wearing a different name.

The hexarelin dosage question, and the answer we can give

We don't provide dosing, titration, or preparation guidance for hexarelin or anything else in the catalog. That isn't evasion, it's the regulatory line. These are research-use-only materials, not drug products, and they are not for human or veterinary consumption. Study parameters reported in published papers belong to those papers and their investigators, and they were set for a specific model under specific conditions.

What's genuinely useful is the concentration framework a laboratory works in. Vial contents are stated in milligrams on the certificate of analysis, and a solution's concentration is expressed in milligrams per millilitre: vial mass divided by solution volume. Every decision downstream of that arithmetic belongs to the investigator and their protocol.

On identity and quality, the verifiable markers are concrete. CAS 140703-51-1, HPLC purity reported at 98% or higher, and mass spectrometry confirming a molecular weight near 887 for the correct hexapeptide sequence. Lyophilized powder is stored at minus 20°C, protected from light and moisture, since short peptides of this type are hygroscopic. Real Peptides supplies hexarelin as a catalog compound for laboratory research, produced through small-batch synthesis with third-party batch analysis.

In our experience, the most valuable pre-procurement step a lab takes is matching the CAS number and the mass-spec trace on the certificate against the exact sequence they intend to study. Everything in this article is research education: hexarelin is not an approved drug product, and nothing here is guidance for use in people.

Hexarelin vs Tesamorelin: two different doors into the GH axis

These two compounds get compared constantly, usually on the wrong axis. The table below sets them side by side on receptor target, structure, regulatory standing, and how each behaves over repeated exposure.

Attribute	Hexarelin	Tesamorelin	Bottom Line
Receptor and pathway	GHS-R1a (the ghrelin receptor), Gq-coupled, acting through phospholipase C and intracellular calcium; also binds CD36 in cardiac tissue	GHRH receptor, Gs-coupled, signalling through cAMP	They engage different receptors entirely, so ranking them by strength misses the point; the pathway determines which endpoints are measurable.
Structure and size	Synthetic hexapeptide, six amino acids, roughly 887 g/mol, CAS 140703-51-1	44-amino-acid GHRH(1-44) analogue carrying a trans-3-hexenoyl modification, roughly 5,100 Da, CAS 218949-48-5	Tesamorelin is about six times the molecular mass and is an analogue of a native hormone; hexarelin is a wholly synthetic short peptide.
Regulatory standing	Research-use-only compound, never approved as a drug product in any jurisdiction	The active ingredient of a prescription drug product authorised for an HIV-associated lipodystrophy indication; research-grade tesamorelin supplied to laboratories is not that drug product	Tesamorelin carries substantially more human clinical-pharmacology data; the hexarelin record is largely preclinical and early clinical.
Behaviour over repeated exposure	Literature reports attenuation of the GH response with continued administration, with partial recovery following washout	Acts on the physiological GHRH pathway, which the literature describes as preserving pulsatile GH release	Desensitization pushes hexarelin studies toward shorter timelines; GHRH-pathway designs tolerate longer arms.
Where research attention sits	GH secretagogue pharmacology, GHS-R1a and CD36 receptor biology, cardiac models	Visceral adipose tissue, IGF-1 response, metabolic endpoints	Select by the receptor question you're asking, not by which compound has the louder reputation.

What If: Hexarelin Research Scenarios

What if I'm looking for hexarelin before and after photographs?

Stop looking, because credible ones don't exist. Hexarelin has never been carried through a long-duration human trial with body-composition endpoints and standardised imaging, which is the only setting that produces defensible visual comparison data. What circulates online is uncontrolled anecdote with unverified compound identity, unknown purity, and no baseline measurement. The desensitization findings in the literature give an additional reason for scepticism about anything claiming sustained results over months.

What if a supplier won't publish a certificate of analysis?

Treat the absence of a published COA as disqualifying. A certificate should state the compound identity, batch number, HPLC purity percentage, and mass spectrometry confirmation matching the expected molecular weight, and it should be independently generated rather than self-reported. Without that document, a laboratory has no way to confirm it received the correct hexapeptide sequence rather than a related GHRP or a degraded batch. Our own batch analyses are published openly.

What if the GH response in a model drops off after the first week?

Check the literature before assuming a compound or storage failure, because attenuation of the GH response to continued GHRP exposure is a documented pharmacological finding rather than an anomaly. Receptor desensitization at GHS-R1a is the mechanism most frequently cited, and studies report partial recovery following a washout interval. Study designs that anticipate this pattern, including washout arms, generate cleaner data than designs that assume a flat response curve.

What if my research question is about adipose tissue rather than receptor biology?

A GHRH analogue is the better-characterised starting point. Tesamorelin's published record is concentrated on visceral adipose tissue and IGF-1 response, while hexarelin's is concentrated on acute secretagogue pharmacology and cardiac receptor work. Choosing hexarelin for a metabolic endpoint means building on a thinner evidence base and accepting the cortisol and prolactin confounds the GHRP class carries.

The unglamorous truth about hexarelin results

Let's be direct about this: nobody can show you a credible hexarelin before and after transformation, because the trial that would produce one has never been run. What exists is acute endocrine pharmacology from the 1990s, receptor characterization work, and animal cardiac studies pointing at CD36. Those findings are genuinely interesting. They are also not the findings this search phrase is hunting for. Anyone presenting transformation imagery as documented evidence is presenting anecdote, and the attenuation data in the literature is a strong reason to distrust anecdotes built on extended use.

If your work sits on the GHRH side of the axis instead, our tesamorelin research page goes deeper on that pathway, and Tesamorelin 10mg is listed with its own batch documentation. Every analysis we hold is published in our COA library, and the full research catalog lists each compound alongside its CAS number and sequence for pre-procurement verification.

The honest framing of hexarelin before and after is that the interesting change isn't in a mirror, it's in a receptor. A hexapeptide designed in the early 1990s turned out to bind a scavenger receptor in heart tissue that nobody had gone looking for, and that finding holds up even in models with no functioning growth hormone axis at all. That's the part of the hexarelin record that has aged well. The photo grids will keep circulating. The CD36 literature is what researchers are still citing three decades on.

References

Peer-reviewed sources on Hexarelin indexed in PubMed, listed for research context. Real Peptides supplies Hexarelin for laboratory research use only.

Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway. European journal of medical research, 2023. PMID 37710348. doi:10.1186/s40001-023-01318-w
Hexarelin attenuates abdominal aortic aneurysm formation by inhibiting SMC phenotype switch and inflammasome activation. Microvascular research, 2022. PMID 34856183. doi:10.1016/j.mvr.2021.104280
Hexarelin modulates lung mechanics, inflammation, and fibrosis in acute lung injury. Drug target insights, 2021. PMID 34871336. doi:10.33393/dti.2021.2347
Hexarelin Modulation of MAPK and PI3K/Akt Pathways in Neuro-2A Cells Inhibits Hydrogen Peroxide-Induced Apoptotic Toxicity. Pharmaceuticals (Basel, Switzerland), 2021. PMID 34066741. doi:10.3390/ph14050444
Using Synchrotron Radiation Imaging Techniques to Elucidate the Actions of Hexarelin in the Heart of Small Animal Models. Frontiers in physiology, 2021. PMID 35126171. doi:10.3389/fphys.2021.766818
Ghrelin receptor agonist hexarelin attenuates antinociceptive tolerance to morphine in rats. Canadian journal of physiology and pharmacology, 2021. PMID 32893668. doi:10.1139/cjpp-2020-0218
Hexarelin targets neuroinflammatory pathways to preserve cardiac morphology and function in a mouse model of myocardial ischemia-reperfusion. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020. PMID 32403043. doi:10.1016/j.biopha.2020.110165
Hexarelin attenuates atherosclerosis via inhibiting LOX-1-NF-κB signaling pathway-mediated macrophage ox-LDL uptake in ApoE(-/-) mice. Peptides, 2019. PMID 31386895. doi:10.1016/j.peptides.2019.170122

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

They measure biochemical endpoints, most commonly serum growth hormone concentration at timed intervals and IGF-1 as a downstream marker, taken from the same subject before and after administration. Cardiac studies in animal models measure functional parameters such as left ventricular performance instead. No published hexarelin research produces the body-composition photo comparison the phrase implies.

There are real published results, but they are endocrine and cardiac data rather than transformation outcomes. Hexarelin has not been run through a long-duration human trial with standardised body-composition imaging, so no credible visual before and after dataset exists. Images circulating online come with no verified compound identity, purity documentation, or controlled baseline.

Hexarelin is an agonist at GHS-R1a, the growth hormone secretagogue receptor that ghrelin binds endogenously. Activation of this Gq-coupled receptor on pituitary somatotrophs drives phospholipase C signalling and a rise in intracellular calcium, triggering growth hormone release while reducing somatostatin tone. Research also identified binding at CD36, a scavenger receptor in cardiac tissue, which mediates cardiovascular actions apparently independent of growth hormone.

Original hexarelin, also called examorelin, is a synthetic hexapeptide developed in the early 1990s within the growth hormone releasing peptide line that started with GHRP-6. Its sequence is His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2, with CAS number 140703-51-1 and a molecular weight of roughly 887 g/mol. Notably, it predates the 1999 identification of ghrelin as the natural ligand for the receptor it targets.

Real Peptides does not provide dosing, titration, or preparation guidance for hexarelin because it is a research-use-only compound, not an approved drug product, and it is not for human or veterinary consumption. What a laboratory works with instead is the concentration framework: vial contents are stated in milligrams on the certificate of analysis, and solution concentration is expressed as milligrams per millilitre. Study parameters in published papers belong to those studies and their investigators.

They act on entirely different receptors. Hexarelin is a six-amino-acid GHS-R1a agonist with a documented secondary binding site at CD36, while tesamorelin is a 44-amino-acid GHRH(1-44) analogue acting at the GHRH receptor through cAMP signalling. Tesamorelin has substantially more human clinical-pharmacology data behind it and a research literature focused on visceral adipose tissue, whereas hexarelin's record centres on acute secretagogue pharmacology and cardiac receptor biology.

The literature reports attenuation of the GH response with repeated hexarelin administration, and receptor-level desensitization at GHS-R1a is the most frequently cited mechanism. Studies also describe partial recovery of the response following a washout interval. This is why an acute single-administration comparison cannot be extrapolated to a multi-week exposure timeline in study design.

The GHRP class as a whole is reported to elevate cortisol and prolactin alongside growth hormone, and hexarelin is described in the literature as less selective in this respect than Ipamorelin. An endocrine panel measuring GH alone will miss those changes entirely. Response attenuation over repeated exposure is the other well-documented complication for study design.

Match three things on the certificate of analysis before ordering: the CAS number 140703-51-1, an HPLC purity figure of 98% or higher, and a mass spectrometry result confirming a molecular weight near 887 for the correct hexapeptide sequence. Independently generated batch documentation matters more than a self-reported purity claim on a product page. Suppliers that won't publish batch analyses should be treated as unverifiable.

Pricing varies widely by purity specification, batch size, and supplier synthesis standards, so any single figure quoted online is unreliable. Research-grade hexarelin is typically supplied as a lyophilized powder with vial contents stated in milligrams and stored at minus 20°C, protected from light and moisture. Real Peptides lists hexarelin as a catalog compound for laboratory research with published third-party batch analysis.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA